WCN26-4080 RETROSPECTIVE ANALYSIS OF RITUXIMAB EFFICACY AND SAFETY IN CHINESE PATIENTS WITH PODOCYTOPATHIES

Read full text Summarise with VIRAT
Authors: Peichen Xie, Liu qianling, Yukun Hu, Yi‐Jen Chen
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Podocytopathies are common pathological subtypes of nephrotic syndrome, encompassing minimal change disease (MCD) and focal segmental glomerulosclerosis (FSGS). Patients with primary podocytopathies frequently experience relapses, glucocorticoid dependence or resistance, complicating disease management, thus underscoring the need for novel alternatives in refractory cases. These disorders are largely immune-mediated and usually show some responsiveness to immunosuppressors. Rituximab (RTX), a monoclonal antibody targeting CD 20, is increasingly being employed in the treatment of refractory podocytopathies.

Fields of Study & Subjects

Renal Diseases and Glomerulopathies Vasculitis and related conditions Renal Transplantation Outcomes and Treatments

Publication details

Journal / source
Kidney International Reports
Volume
11
Issue
4
Pages
105603–105603
Publication date
25 March 2026
Language
EN